To amend the Federal Food, Drug, and Cosmetic Act and Public Health Service Act to advance the next-generation of clinical development of novel treatments and cures, and for other purposes.
Summary
HR10857, introduced Oct 22, 2026, proposes amendments to FDA and PHS Act to modernize clinical development for novel treatments. The bill is in early committee stage with bipartisan sponsorship. A recent executive order on women's health reinforces the administration's focus on healthcare innovation, providing a tailwind for the bill's objectives.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR10857 is an early-stage authorization bill to modernize FDA clinical trial regulations, with no direct funding but potential to reduce drug development costs.
- 2.Bipartisan sponsorship and alignment with a recent executive order on women's health increase the bill's legislative momentum.
- 3.Biotech and diagnostics companies with innovative trial approaches are primary beneficiaries, including $VRTX, $NTLA, $ILMN, $ISRG, $HOLX, $MYGN, and $OGN.
Market Implications
The bill's impact on the healthcare sector is uncertain due to its early stage. However, the convergence with the executive order on women's health signals a broader administration push for clinical innovation. Companies like $VRTX and $ILMN, which are already investing in next-generation trial methods, are well-positioned to capitalize on regulatory modernization. Investors should watch for committee markups and any specific provisions that emerge, as they will clarify the magnitude of impact.
Full Analysis
HR10857 was introduced in the House on October 22, 2026, by Rep. Jake Auchincloss (D-MA) and cosponsored by Rep. H. Morgan Griffith (R-VA), giving it bipartisan cover. The bill was referred to the Committees on Energy and Commerce and Ways and Means, indicating it involves both healthcare regulatory policy and tax implications. As an authorization bill, it does not appropriate funds but would direct FDA to modernize clinical trial regulations, potentially including adaptive trials, real-world evidence, and decentralized trial models.
The money trail is indirect: the bill does not authorize specific spending but would reduce regulatory barriers, lowering clinical trial costs for drug developers. Companies with large R&D pipelines and innovative trial approaches stand to benefit most. The recent executive order on women's health, signed Oct 19, 2026, aligns with the bill's goal of advancing clinical development, specifically targeting women's health outcomes. This convergence suggests the administration is prioritizing healthcare innovation, increasing the likelihood of eventual passage.
Structural winners include biotech and diagnostics companies that are early adopters of next-generation clinical trial methods. Vertex ($VRTX) and Intellia ($NTLA) are leaders in gene therapy and gene editing, where trial innovation can significantly reduce development timelines. Illumina ($ILMN) provides genomic sequencing essential for precision medicine trials. Intuitive Surgical ($ISRG) generates real-world data from its installed base of surgical robots. Diagnostics companies Hologic and Myriad Genetics ($MYGN) offer tools for patient stratification and monitoring. Organon ($OGN) focuses on women's health, directly benefiting from the executive order's emphasis.
Timeline: The bill is in early stages. It must pass through both committees, then the House floor, then the Senate, and be signed by the President. Given the bipartisan sponsorship and alignment with administration priorities, it has a moderate chance of passage in this Congress, but actual market impact depends on the final regulatory changes enacted.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Regulatory modernization for next-generation clinical development, including adaptive trial designs and real-world evidence integration.
Who must act
FDA and drug developers conducting clinical trials.
What happens
Reduced clinical trial costs and accelerated time-to-market for novel treatments.
Stock impact
Vertex's gene therapy pipeline (e.g., CTX001 for sickle cell disease) benefits from faster, lower-cost trials, improving pipeline ROI.
What the bill does
Same regulatory modernization for clinical development.
Who must act
FDA and drug developers.
What happens
Faster approval pathways for gene-editing therapies.
Stock impact
Intellia's in vivo gene editing programs (e.g., NTLA-2001 for transthyretin amyloidosis) see reduced development timelines.
Key Legislators
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
A bill to amend the Internal Revenue Code of 1986 to exclude from gross income certain compensation to clinical trial participants, and for other purposes.
Clinical Trial Modernization Act
SEQIRUS INC: $42.8M Department of Health and Human Services Contract
Advancing Menopause Care and Mid-Life Women’s Health Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Adjusting Imports of Wind Turbines and Their Parts and Components into the United States
This proclamation initiates negotiations to adjust imports of wind turbines and their components under Section 232, citing national security concerns including cybersecurity vulnerabilities, radar interference, and grid reliability. It does not immediately impose tariffs but sets the stage for potential trade restrictions, and notes that certain wind turbine components made of aluminum, steel, or copper are already subject to existing tariffs.
Advancing Women's Health to Improve Outcomes in All Phases of Life
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
Streamlining Access to Government Services Through America.gov
The executive order directs the General Services Administration to create America.gov, a unified digital portal for federal services, integrating Login.gov for authentication and requiring agencies to expose their digital services via APIs. It also mandates the use of AI (referred to as 'super intelligence') with transparency safeguards, while preserving existing service channels and excluding tax and defense/intelligence services.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →